Übersicht – Neue diagnostische Ansätze bei Lymphomen

• Literatur

• 1 Nowakowski GS, Czuczman MS. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?. Am Soc Clin Oncol Educ Book 2015; e449-e457
• 2 Zappasodi R, de Braud F, Di Nicola M. Lymphoma Immunotherapy: Current Status. Front Immunol 2015; 6: 448
• 3 van Dongen JJ, Langerak AW, Bruggemann M et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia 2003; 17: 2257-2317
• 4 Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed / refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer 2015; 14: 207
• 5 Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511
• 6 Meyer PN, Fu K, Greiner TC et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29: 200-207
• 7 Scott DW, Wright GW, Williams PM et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123: 1214-1217
• 8 Wilson WH, Young RM, Schmitz R et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21: 922-926
• 9 Fowler NH, Cheah CY, Gascoyne RD et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 2016; 101: 531-540
• 10 Aukema SM, Siebert R, Schuuring E et al. Double-hit B-cell lymphomas. Blood 2011; 117: 2319-2331